Candidate Compounds Covid19

(Unterschied zwischen Versionen)

Wechseln zu: Navigation, Suche

Version vom 28. Juni 2020, 11:09 Uhr

coviki.org collects the really good Ideas and the scientific Record on Covid-19 Virus.

current items will be put into the subsections.

other single compounds
Retargeted single compounds
Hydroxychloroquine
Target ACE2, Spike protein
Target TMPRSS2, Spike protein any other covid targed herein
other antiviral compounds
AV Remdesivir
AV Lopinavir
AV Ivermectin
AV Arabidol
AV Favipiravir

Immunodeviation e.g. by adjuvants or other vaccinations
Radiation therapy
Phototherapy
Active vaccine

-rest-

32458400 2020. Implications for Neuromodulation Therapy to Control Inflammation and Related Organ Dysfunction in COVID-19.
32401611 2020. The pulmonary-proteoliposome as a new therapeutic approach for Coronaviruses.
32413736 2020. Towards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, and corticosteroids.
32450201 2020. Side effects of ruxolitinib in patients with SARS-CoV-2 infection: Two case reports.
32522674 2020. Widely available lysosome targeting agents should be considered as potential therapy for COVID-19.
32534188 2020. Severe Acute Respiratory Syndrome Coronavirus -2 (SARS-CoV-2): A global pandemic and treatments strategies.

32534094 2020. Antiviral activity of the high-molecular-weight plant polysaccharides (Panavir(R)).

32460369 2020. Non-steroidal anti-inflammatory drugs in management of COVID-19; A systematic review on current evidence.
32412158 2020. Indomethacin and resveratrol as potential treatment adjuncts for SARS-CoV-2/COVID-19.
32531935 2020. Chronic Inflammation in the Context of Everyday Life: Dietary Changes as Mitigating Factors.

32411575 2020. Malnutrition Care during the COVID-19 Pandemic: Considerations for Registered Dietitian Nutritionists Evidence Analysis Center.

32470486 2020. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial.

32527713 2020. In Silico computational screening of Kabasura Kudineer - Official Siddha Formulation and JACOM against SARS-CoV-2 spike protein.

32396773 2020. Truncated human angiotensin converting enzyme 2; a potential inhibitor of SARS-CoV-2 spike glycoprotein and potent COVID-19 therapeutic agent.

32384202 2020. Home-based training strategy to maintain muscle function in older adults with diabetes during COVID-19 confinement.

32509284 2020. The need to implement non-industry COVID-19 clinical trials in non-high-income countries.

32533263 2020. Intracellular ABCB1 as a Possible Mechanism to Explain the Synergistic Effect of Hydroxychloroquine-Azithromycin Combination in COVID-19 Therapy.

32469114 2020. An update on ACE2 amplification and its therapeutic potential.

32315803 2020. Preliminary therapeutic drug monitoring data of beta-lactams in critically ill patients with SARS-CoV-2 infection.

32519894 2020. Heparin as a Therapy for COVID-19: Current Evidence and Future Possibilities.

32499129 2020. Immunotherapies for COVID-19: Restoring the immunity could be the priority.

32534022 2020. COVID-19 and allergen immunotherapy: theoretical benefits invite to adjustments in practice recommendations.

32405693 2020. Could ruxolitinib be effective in patients with COVID-19 infection at risk of acute respiratory distress syndrome (ARDS)?

32345532 2020. Response to: Bioactive Lipids and Coronavirus (COVID-19)-further Discussion.

32399093 2020. Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic.

32470547 2020. Targeting Neprilysin (NEP) pathways: A potential new hope to defeat COVID-19 ghost.

32532623 2020. Fighting COVID-19: A quick review of diagnoses, therapies, and vaccines.

32383371 2020. Perspectives of Immune Therapy in Coronavirus Disease 2019.

32401215 2020. Telehealth Home Support During COVID-19 Confinement for Community-Dwelling Older Adults With Mild Cognitive Impairment or Mild Dementia: Survey Study.

32468385 2020. Musings on the current state of COVID-19 modeling and reporting.
32435882 2020. Model based approach for estimating the dosage regimen of indomethacin a potential antiviral treatment of patients infected with SARS CoV-2.

32452670 2020. Immunity-Boosting Spices and the Novel Coronavirus.

32396382 2020. Myth Busters: Dietary Supplements and COVID-19.

32523144 2020. Protocolo para la prevencion de arritmias ventriculares debido al tratamiento en pacientes con COVID-19.
32518135 2020. Paediatric treatment trials for COVID-19 are an ethical imperative.
32522067 2020. Autophagy as an emerging target for COVID-19: lessons from an old friend, chloroquine.
32521191 2020. Open questions for harnessing autophagy-modulating drugs in the SARS-CoV-2 war: hope or hype?
32515023 2020. A call for the appropriate application of clinical pharmacological principles in the search for safe and efficacious COVID-19 (SARS-COV-2) treatments.

32520031 2020. In silico evaluation of marine fish proteins as nutritional supplements for COVID-19 patients.

32516380 2020. Covid-19's Impact on Podiatry in Chicago's Largest Public Hospital.

32390307 2020. Practical tips for using masks in the COVID-19 pandemic.
32358890 2020. Cutaneous side-effects of the potential COVID-19 drugs.

32428864 2020. Angiotensin converting enzyme-2 as therapeutic target in COVID-19.

32514859 2020. Drug-Induced Liver Injury and COVID-19 Infection: The Rules Remain the Same.

32378805 2020. COVID-19 and toxicity from potential treatments: Panacea or poison.
32475694 2020. Reflexions autour d'une evolution favorable d'une COVID-19 chez un patient presentant une schizophrenie resistante et sous une association clozapine et paliperidone palmitate.
32482569 2020. Nutricion Clinica en tiempos de COVID-19.

32518390 2020. Editorial: Nutrition and COVID-19.
32433599 2020. Nutritional management of COVID-19 patients in a rehabilitation unit.
32404899 2020. Clinical significance of nutritional risk screening for older adult patients with COVID-19.

32398309 2020. Could the smoking gun in the fight against Covid-19 be the (rh) ACE2?

32398976 2020. siRNA could be a potential therapy for COVID-19.

32425923 2020. Could the Inhibition of Endo-Lysosomal Two-Pore Channels (TPCs) by the Natural Flavonoid Naringenin Represent an Option to Fight SARS-CoV-2 Infection?

32468851 2020. Facing the SARS-CoV-2 outbreak in the immunotherapy era.
32406749 2020. Oncology clinical trials in the time of COVID-19: how a pandemic can revolutionize patients' care.

32535509 2020. COVID-19, interferons, and depression: A commentary.

32470338 2020. MORTALITY FROM COVID-19 INCREASES WITH UNSATURATED FAT, AND MAY BE REDUCED BY EARLY CALCIUM AND ALBUMIN SUPPLEMENTATION.

007

32496248 2020. Effectiveness of preventive measures against COVID-19: A systematic review of In Silico modeling studies in indian context.
32496246 2020. Impact of nonpharmacological interventions on COVID-19 transmission dynamics in India.

32429572 2020. The Role of Lipid Metabolism in COVID-19 Virus Infection and as a Drug Target.

32408699 2020. Essential Oils as Antiviral Agents. Potential of Essential Oils to Treat SARS-CoV-2 Infection: An In-Silico Investigation.

32455942 2020. Potential Therapeutic Targeting of Coronavirus Spike Glycoprotein Priming.

32457038 2020. Potential COVID-19 therapeutics from a rare disease: Weaponizing lipid dysregulation to combat viral infectivity.

32423974 2020. COVID-19 and Rheumatology patients on immunomodulatory therapy - can we extrapolate data from previous viral pandemics?

32475104 2020. Coronavirus Disease 2019 Presenting as Conjunctivitis.

32162896 2020. Possible therapeutic role of a highly standardized mixture of active compounds derived from cultured Lentinula edodes mycelia (AHCC) in patients infected with 2019 novel coronavirus.

32418757 2020. Pancreatic cancer: Does a short course of carbon ion radiotherapy worth during COVID-19 outbreak?

32505040 2020. The end of 'cordon sanitaire' in Wuhan: the role of non-pharmaceutical interventions against COVID-19.

32472939 2020. Assessing the impact of non-pharmaceutical interventions on SARS-CoV-2 transmission in Switzerland.

32500793 2020. Repurposing Nimesulide, a Potent Inhibitor of the B0AT1 Subunit of the SARS-CoV-2 Receptor, as a Therapeutic Adjuvant of COVID-19.

32491981 2020. Nonpharmaceutical Measures for Pandemic Influenza in Nonhealthcare Settings-International Travel-Related Measures.
32487283 2020. Effect of Nonpharmaceutical Interventions on Transmission of Severe Acute Respiratory Syndrome Coronavirus 2, South Korea, 2020.

32403995 2020. Development of multi-specific humanized llama antibodies blocking SARS-CoV-2/ACE2 interaction with high affinity and avidity.

32496237 2020. AYUSH for COVID-19: Science or Superstition?

32460209 2020. The effect of potential therapeutic agents on QT interval in patients with COVID-19 Infection: The importance of close monitoring and correction of electrolytes.

32487990 2020. Modeling mitigation of influenza epidemics by baloxavir.

32438383 2020. Inhaled modified angiotensin converting enzyme 2 (ACE2) as a decoy to mitigate SARS-CoV-2 infection.

32512579 2020. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe.

32501634 2020. Can Hypericum perforatum (SJW) prevent cytokine storm in COVID-19 patients?

32116200 2020. COVID-19: Perspectives on the Potential Novel Global Threat.

32294756 2020. Intervencoes nao farmacologicas para o enfrentamento a epidemia da COVID-19 no Brasil.

32448098 2020. Structural and simulation analysis of hotspot residues interactions of SARS-CoV 2 with human ACE2 receptor.

32458425 2020. Compassionate use of hzVSF-v13 in two patients with severe COVID-19.

32463459 2020. Prescription Fill Patterns for Commonly Used Drugs During the COVID-19 Pandemic in the United States.

32498081 2020. Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).

32310670 2020. Public Health Approach of Ayurveda and Yoga for COVID-19 Prophylaxis.

32485061 2020. Incidence and Determinants of QT Interval Prolongation in COVID-19 Patients Treated with Hydroxychloroquine and Azithromycin.

32473010 2020. TPE-nAbs combination therapy for severe COVID-19.

32472703 2020. COVID-19 pneumonia treated with Sarilumab: A clinical series of eight patients.

32464736 2020. A simulation training course for family medicine residents in China managing COVID-19.

32442317 2020. The case for Chronotherapy in COVID-19 induced Acute Respiratory Distress Syndrome (ARDS).

32449802 2020. May we target double membrane vesicles and oxysterol-binding protein to combat SARS-CoV-2 infection?

32449939 2020. SARS-CoV-2 spike glycoprotein-binding proteins expressed by upper respiratory tract bacteria may prevent severe viral infection.

32493028 2020. Letter to the Editor: Repurposing of an Antisepsis Drug in COVID-19 Patients.

32403134 2020. Combination dose-escalated hydroxyurea and transfusion: an approach to conserve blood during the COVID-19 pandemic.

32303505 2020. Covid-19: ibuprofen can be used for symptoms, says UK agency, but reasons for change in advice are unclear.
32407551 2020. Interrogation of the safety and efficacy of home-use light-based devices.

32429705 2020. COVID-19 and Nutrition: The Need for Initiatives to Promote Healthy Eating and Prevent Obesity in Childhood.
32412788 2020. beta-Arrestin-Biased Angiotensin II Receptor Agonists for COVID-19.

32442315 2020. Alternative splicing of ACE2 possibly generates variants that may limit the entry of SARS-CoV-2: a potential therapeutic approach using SSOs.

32510814 2020. Omalizumab and COVID19 Treatment: Could It Help?

32510719 2020. Intramatricial methotrexate for treatment of resistant acrodermatitis continua of Hallopeau: an alterative in Covid-19.
32500633 2020. "Thinking outside the box in COVID-19 era"-Application of Modified Aerosol Box in Dermatology.

32503855 2020. Candidate rheumatologic treatments for COVID-19. Response to: 'COVID-19 infection in a patient with FMF: does colchicine have a protective effect?' by Kobak.

32229705 2020. Geroprotective and senoremediative strategies to reduce the comorbidity, infection rates, severity, and lethality in gerophilic and gerolavic infections
32276453 2020. Exploring the Relevance of Senotherapeutics for the Current SARS-CoV-2 Emergency and Similar Future Global Health Threats
32325124 ä. Vaporization, bioactive formulations and a marine natural product: different perspectives on antivirals
32312129 2020. The role of additive manufacturing and antimicrobial polymers in the COVID-19 pandemic
32336674 ä. COVID-19 Emergency Responders in FDA?s Center for Drug Evaluation and Research
32356251 ä. Medical Toxicology and COVID-19: Our Role in a Pandemic
32243778 2020. Ensuring global access to COVID-19 vaccines
32247324 2020. Global coalition to accelerate COVID-19 clinical research in resource-limited settings
32272857 2020. Role of Tissue Engineering in COVID-19 and Future Viral Outbreaks
C7190525 2020. Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients
32129977 2020. Cell-Membrane-Mimicking Nanodecoys against Infectious Diseases
29115746 2018. Progress Toward the Clinical Translation of Bioinspired Peptide and Protein Assemblies
29717819 2018. Recent Advances in the Development of Antimicrobial Nanoparticles for Combating Resistant Pathogens
C7194243 ä. Coronavirus Disease 2019 (COVID-19) Spread and Pharmacovigilance Implications: Expert Opinion
32383008 ä. The Role of Pharmacovigilance and ISoP During the Global COVID-19 Pandemic
32380052 2020. Granulocyte-targeted therapies for airway diseases
32452420 2020. Antiviral activity of lycorine against Zika virus in vivo and in vitro

Candidate Compounds Covid19

Version vom 28. Juni 2020, 11:09 Uhr

coviki.org collects the really good Ideas and the scientific Record on Covid-19 Virus.

-rest-

007

Meine Werkzeuge

Namensräume

Varianten

Ansichten

Aktionen

Suche

Navigation

Werkzeuge

@@ Zeile 72: / Zeile 72: @@
 *[[Active vaccine]]
-===008===
+===-rest-===
 {{tp|p=32458400|t=2020. Implications for Neuromodulation Therapy to Control Inflammation and Related Organ Dysfunction in COVID-19.|pdf=|usr=008}}
 {{tp|p=32401611|t=2020. The pulmonary-proteoliposome as a new therapeutic approach for Coronaviruses.|pdf=|usr=008}}
 {{tp|p=32413736|t=2020. Towards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, and corticosteroids.|pdf=|usr=008}}
 {{tp|p=32450201|t=2020. Side effects of ruxolitinib in patients with SARS-CoV-2 infection: Two case reports.|pdf=|usr=008}}
 {{tp|p=32522674|t=2020. Widely available lysosome targeting agents should be considered as potential therapy for COVID-19.|pdf=|usr=008}}
 {{tp|p=32534188|t=2020. Severe Acute Respiratory Syndrome Coronavirus -2 (SARS-CoV-2): A global pandemic and treatments strategies.|pdf=|usr=008}}
@@ Zeile 536: / Zeile 519: @@
-{{tp|p=32462858|t=2020. Oxygen-ozone therapy as adjuvant in the current emergency in SARS-COV-2 infection: a clinical study.|pdf=|usr=007}}
-{{tp|p=32469279|t=2020. Withanone and Withaferin-A are predicted to interact with transmembrane protease serine 2 (TMPRSS2) and block entry of SARS-CoV-2 into cells.|pdf=|usr=007}}
-{{tp|p=32462988|t=2020. A computational prediction of SARS-CoV-2 structural protein inhibitors from Azadirachta indica (Neem).|pdf=|usr=007}}
-{{tp|p=32475223|t=2020. Antiviral effects of probiotic metabolites on COVID-19.|pdf=|usr=007}}
-{{tp|p=32462970|t=2020. Identification of potential inhibitors of SARS-COV-2 endoribonuclease (EndoU) from FDA approved drugs: a drug repurposing approach to find therapeutics for COVID-19.|pdf=|usr=007}}
-{{tp|p=32462996|t=2020. Molecular docking, simulation and MM-PBSA studies of nigella sativa compounds: a computational quest to identify potential natural antiviral for COVID-19 treatment.|pdf=|usr=007}}
-{{tp|p=32476574|t=2020. Virtual screening-driven drug discovery of SARS-CoV2 enzyme inhibitors targeting viral attachment, replication, post-translational modification and host immunity evasion infection mechanisms.|pdf=|usr=007}}
 {{tp|p=32485061|t=2020. Incidence and Determinants of QT Interval Prolongation in COVID-19 Patients Treated with Hydroxychloroquine and Azithromycin.|pdf=|usr=007}}
-{{tp|p=32433345|t=2020. The pharmacological development of direct acting agents for emerging needed therapy against SARS-CoV-2.|pdf=|usr=007}}
-{{tp|p=32473011|t=2020. Potential inhibition of COVID-19-driven pneumonia by immunosuppressive therapy and anti-TNFalpha antibodies: a case report.|pdf=|usr=007}}
-{{tp|p=32504739|t=2020. Interleukin-17: A potential therapeutic target in COVID-19.|pdf=|usr=007}}
 {{tp|p=32473010|t=2020. TPE-nAbs combination therapy for severe COVID-19.|pdf=|usr=007}}
-{{tp|p=32220033|t=2020. Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19).|pdf=|usr=007}}
-{{tp|p=32511912|t=2020. COVID-19: Drug targets and potential treatments.|pdf=|usr=007}}
-{{tp|p=32469301|t=2020. Potential RNA-dependent RNA polymerase inhibitors as prospective therapeutics against SARS-CoV-2.|pdf=|usr=007}}
 {{tp|p=32472703|t=2020. COVID-19 pneumonia treated with Sarilumab: A clinical series of eight patients.|pdf=|usr=007}}
-{{tp|p=32427773|t=2020. Rescue Therapy for Severe COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) with Tissue Plasminogen Activator (tPA): A Case Series.|pdf=|usr=007}}
-{{tp|p=32364561|t=2020. Randomized Clinical Trials and COVID-19: Managing Expectations.|pdf=|usr=007}}
-{{tp|p=32463427|t=2020. Using Controlled Trials to Resolve Key Unknowns About Policy During the COVID-19 Pandemic.|pdf=|usr=007}}
-{{tp|p=32453363|t=2020. No Benefit for Lopinavir-Ritonavir in Severe COVID-19.|pdf=|usr=007}}
-{{tp|p=32506195|t=2020. Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19.|pdf=|usr=007}}
-{{tp|p=32463794|t=2020. Metformin and SARS-CoV-2: mechanistic lessons on air pollution to weather the cytokine/thrombotic storm in COVID-19.|pdf=|usr=007}}
-{{tp|p=32434272|t=2020. COVID-19Clinical trials: quality matters more than quantity.|pdf=|usr=007}}
 {{tp|p=32464736|t=2020. A simulation training course for family medicine residents in China managing COVID-19.|pdf=|usr=007}}
-{{tp|p=32505821|t=2020. Analysis of the molecular mechanism of Pudilan (PDL) treatment for COVID-19 by network pharmacology tools.|pdf=|usr=007}}
-{{tp|p=32455629|t=2020. Tripartite Combination of Candidate Pandemic Mitigation Agents: Vitamin D, Quercetin, and Estradiol Manifest Properties of Medicinal Agents for Targeted Mitigation of the COVID-19 Pandemic Defined by Genomics-Guided Tracing of SARS-CoV-2 Targets in Human Cells.|pdf=|usr=007}}
-{{tp|p=32398343|t=2020. Should azithromycin be used to treat COVID-19? A rapid review.|pdf=|usr=007}}
-{{tp|p=32454500|t=2020. Extracorporeal Blood Purification and Organ Support in the Critically Ill Patient during COVID-19 Pandemic: Expert Review and Recommendation.|pdf=|usr=007}}
-{{tp|p=32453693|t=2020. Rebuttal to letter "Is thromboprophylaxis with high-dose enoxaparin really necessary for COVID-19 patients? A new "prudent" randomised clinical trial".|pdf=|usr=007}}
-{{tp|p=32453692|t=2020. Is thromboprophylaxis with high-dose enoxaparin really necessary for COVID-19 patients? A new "prudent" randomised clinical trial.|pdf=|usr=007}}
-{{tp|p=32267762|t=2020. Research towards treating COVID-19.|pdf=|usr=007}}
-{{tp|p=32433778|t=2020. Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19.|pdf=|usr=007}}
 {{tp|p=32442317|t=2020. The case for Chronotherapy in COVID-19 induced Acute Respiratory Distress Syndrome (ARDS).|pdf=|usr=007}}
-{{tp|p=32441783|t=2020. A rationale for targeting the P2X7 receptor in Coronavirus disease 19 (Covid-19).|pdf=|usr=007}}
-{{tp|p=32441764|t=2020. Repositioning PARP inhibitors for SARS-CoV-2 infection (COVID-19); a new multi-pronged therapy for ARDS?|pdf=|usr=007}}
-{{tp|p=32424836|t=2020. Lung tissue distribution of drugs as a key factor for COVID-19 treatment.|pdf=|usr=007}}
 {{tp|p=32449802|t=2020. May we target double membrane vesicles and oxysterol-binding protein to combat SARS-CoV-2 infection?|pdf=|usr=007}}
-{{tp|p=32512007|t=2020. Efficacy of Almitrine in The Treatment of Hypoxemia in Sars-Cov-2 Acute Respiratory Distress Syndrome.|pdf=|usr=007}}
-{{tp|p=32445484|t=2020. A Real-World Evidence Framework for Optimising Dosing in All Patients with COVID-19.|pdf=|usr=007}}
-{{tp|p=32438446|t=2020. Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics.|pdf=|usr=007}}
-{{tp|p=32508009|t=2020. Thalidomide combined with low-dose short-term glucocorticoid in the treatment of critical Coronavirus Disease 2019.|pdf=|usr=007}}
-{{tp|p=32441462|t=2020. Time to Step Up: A Call to Action For the Clinical and Quantitative Pharmacology Community to Accelerate Therapeutics for COVID-19.|pdf=|usr=007}}
-{{tp|p=32511867|t=2020. Predictions of Systemic, Intracellular, and Lung Concentrations of Azithromycin with Different Dosing Regimens used in COVID-19 Clinical Trials.|pdf=|usr=007}}
-{{tp|p=32418327|t=2020. Ligand-centered assessment of SARS-CoV-2 drug target models in the Protein Data Bank.|pdf=|usr=007}}
 {{ttp|p=32449939|t=2020. SARS-CoV-2 spike glycoprotein-binding proteins expressed by upper respiratory tract bacteria may prevent severe viral infection.|pdf=|usr=007}}
-{{tp|p=32420947|t=2020. Stop playing with data: there is no sound evidence that Bacille Calmette-Guerin may avoid SARS-CoV-2 infection (for now).|pdf=|usr=007}}
-{{tp|p=32420936|t=2020. Treatments for COVID-19: emerging drugs against the coronavirus.|pdf=|usr=007}}
-{{tp|p=32425152|t=2020. Medicines for the Treatment Of COVID-19: Awaiting the Evidence.|pdf=|usr=007}}
-{{tp|p=32506621|t=2020. Drugs being investigated for children with COVID-19.|pdf=|usr=007}}
-{{tp|p=32423954|t=2020. Accelerating drug development through repurposed FDA approved drugs for COVID-19: speed is important, not haste.|pdf=|usr=007}}
 {{tp|p=32493028|t=2020. Letter to the Editor: Repurposing of an Antisepsis Drug in COVID-19 Patients.|pdf=|usr=007}}
-{{tp|p=32510142|t=2020. alpha-glucosidase inhibitors as host-directed antiviral agents with potential for the treatment of COVID-19.|pdf=|usr=007}}
-{{tp|p=32407491|t=2020. iBioProVis: Interactive Visualization and Analysis of Compound Bioactivity Space.|pdf=|usr=007}}
 {{tp|p=32403134|t=2020. Combination dose-escalated hydroxyurea and transfusion: an approach to conserve blood during the COVID-19 pandemic.|pdf=|usr=007}}
-{{tp|p=32345591|t=2020. RECOVERY trial: the UK covid-19 study resetting expectations for clinical trials.|pdf=|usr=007}}
 {{tp|p=32303505|t=2020. Covid-19: ibuprofen can be used for symptoms, says UK agency, but reasons for change in advice are unclear.|pdf=|usr=007}}
 {{tp|p=32407551|t=2020. Interrogation of the safety and efficacy of home-use light-based devices.|pdf=|usr=007}}
-{{tp|p=32480418|t=2020. Harnessing HLA-E-restricted CD8 T lymphocytes for adoptive cell therapy of severe COVID-19 patients.|pdf=|usr=007}}
-{{tp|p=32498751|t=2020. Drug Repurposing for COVID-19: Ethical Considerations and Roadmaps.|pdf=|usr=007}}
 {{tp|p=32429705|t=2020. COVID-19 and Nutrition: The Need for Initiatives to Promote Healthy Eating and Prevent Obesity in Childhood.|pdf=|usr=007}}
 {{tp|p=32412788|t=2020. beta-Arrestin-Biased Angiotensin II Receptor Agonists for COVID-19.|pdf=|usr=007}}
-{{tp|p=32503806|t=2020. The World of Clinical Trial Development Post-Covid-19: Lessons Learned from a Global Pandemic.|pdf=|usr=007}}
-{{tp|p=32474583|t=2020. In Reply: COVID-19: An Argument for Rapid Access to Laboratory Data Warehouses.|pdf=|usr=007}}
-{{tp|p=32459003|t=2020. A role for retinoids in the treatment of COVID-19?|pdf=|usr=007}}
-{{tp|p=32459832|t=2020. Importance of Pediatric Inclusion in COVID-19 Therapeutic Trials.|pdf=|usr=007}}
-{{tp|p=32442287|t=2020. Thymosin alpha 1 (Talpha1) reduces the mortality of severe COVID-19 by restoration of lymphocytopenia and reversion of exhausted T cells.|pdf=|usr=007}}
@@ Zeile 636: / Zeile 599: @@
-{{tp|p=32498131|t=2020. Pandemic Best Regulatory Practices: An Urgent Need in the Covid-19 Pandemic.|pdf=|usr=007}}
-{{tp|p=32350861|t=2020. COVID-19: A Defining Moment for Clinical Pharmacology?|pdf=|usr=007}}
 {{tp|p=32442315|t=2020. Alternative splicing of ACE2 possibly generates variants that may limit the entry of SARS-CoV-2: a potential therapeutic approach using SSOs.|pdf=|usr=007}}
-{{tp|p=32212378|t=2020. Optimizing COVID-19 Candidate Therapeutics: Thinking Without Borders.|pdf=|usr=007}}
-{{tp|p=32284037|t=2020. Perspective on the COVID-19 Coronavirus Outbreak.|pdf=|usr=007}}
-{{tp|p=32174284|t=2020. A Generic Computer-Assisted Four-Pronged Approach for the Management of Emerging Global Pathogens: Some Comments on COVID-19.|pdf=|usr=007}}
-{{tp|p=32400323|t=2020. In vitro data of current therapies for SARS-CoV-2.|pdf=|usr=007}}
-{{tp|p=32427000|t=2020. Implications of the lack of a unified research project framework: an investigation into the registration of clinical trials of COVID-19.|pdf=|usr=007}}
+{{tp|p=32510814|t=2020. Omalizumab and COVID19 Treatment: Could It Help?|pdf=|usr=007}}
-{{tp|p=32416679|t=2020. Novel Drugs Targeting the SARS-CoV-2/COVID-19 Machinery.|pdf=|usr=007}}
-{{tp|p=32394841|t=2020. COVID-19: An Update on Clinical Trials.|pdf=|usr=007}}
-{{tp|p=32282303|t=2020. Coronavirus Disease (COVID-19) Pandemic: A Race Against Time.|pdf=|usr=007}}
-{{tp|p=32475041|t=2020. Potential role of Anti-IL-17 in COVID-19 treatment.|pdf=|usr=007}}
-{{tp|p=32473070|t=2020. Treatment of COVID-19 with pentoxifylline: Could it be a potential adjuvant therapy?|pdf=|usr=007}}
-{{tp|p=32510814|t=2020. Omalizumab and COVID19 Treatment: Could It Help?|pdf=|usr=007}}
-{{tp|p=32510734|t=2020. Azithromycin and COVID-19Prompt Early Use at First Signs of this Infection in Adults and Children An Approach Worthy of Consideration.|pdf=|usr=007}}
 {{tp|p=32510719|t=2020. Intramatricial methotrexate for treatment of resistant acrodermatitis continua of Hallopeau: an alterative in Covid-19.|pdf=|usr=007}}
 {{tp|p=32500633|t=2020. "Thinking outside the box in COVID-19 era"-Application of Modified Aerosol Box in Dermatology.|pdf=|usr=007}}
-{{tp|p=32419517|t=2020. Emerging therapies for COVID-19 pneumonia.|pdf=|usr=007}}
-{{tp|p=32429703|t=2020. SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review.|pdf=|usr=007}}
-{{tp|p=32419524|t=2020. Old and re-purposed drugs for the treatment of COVID-19.|pdf=|usr=007}}
-{{tp|p=32223349|t=2020. How could artificial intelligence aid in the fight against coronavirus?|pdf=|usr=007}}
-{{tp|p=32500928|t=2020. COVID-19 breakthroughs: separating fact from fiction.|pdf=|usr=007}}
-{{tp|p=32419212|t=2020. Granulocyte-colony stimulating factor in COVID-19: Is it stimulating more than just the bone marrow?|pdf=|usr=007}}
-{{tp|p=32401673|t=2020. Urgent reconsideration of lung edema as a preventable outcome in COVID-19: inhibition of TRPV4 represents a promising and feasible approach.|pdf=|usr=007}}
-{{tp|p=32428965|t=2020. Exclusion of Pregnant Women from Clinical Trials during the Coronavirus Disease 2019 Pandemic: A Review of International Registries.|pdf=|usr=007}}
-{{tp|p=32479158|t=2020. Reply to Jakovac; Severity of COVID-19 infection in patients with phenylketonuria: is vitamin D status protective?|pdf=|usr=007}}
-{{tp|p=32464083|t=2020. P-selectin blockade in COVID-19-related ARDS.|pdf=|usr=007}}
-{{tp|p=32437628|t=2020. COVID-19, Asthma, and Inhaled Corticosteroids (ICS): Another Beneficial Effect of ICS?|pdf=|usr=007}}
-{{tp|p=32446312|t=2020. Metformin Treatment Was Associated with Decreased Mortality in COVID-19 Patients with Diabetes in a Retrospective Analysis.|pdf=|usr=007}}
 {{tp|p=32503855|t=2020. Candidate rheumatologic treatments for COVID-19. Response to: 'COVID-19 infection in a patient with FMF: does colchicine have a protective effect?' by Kobak.|pdf=|usr=007}}
-{{tp|p=32340978|t=2020. The conundrum of COVID-19 treatment targets: the close correlation with rheumatology. Response to: 'Management of rheumatic diseases in the time of covid-19 pandemic: perspectives of rheumatology pracitioners from India' by Gupta et al and 'Antirheumatic agents in covid-19: is IL-6 the right target?' by Capeechi et al.|pdf=|usr=007}}
--rest-
 {{tp|p=32229705|t=2020. Geroprotective and senoremediative strategies to reduce the comorbidity, infection rates, severity, and lethality in gerophilic and gerolavic infections |pdf=|usr=}}
 {{tp|p=32276453|t=2020. Exploring the Relevance of Senotherapeutics for the Current SARS-CoV-2 Emergency  and Similar Future Global Health Threats |pdf=|usr=}}